These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27481049)

  • 1. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
    Reeves S; Bertrand J; D'Antonio F; McLachlan E; Nair A; Brownings S; Greaves S; Smith A; Taylor D; Howard R
    Psychopharmacology (Berl); 2016 Sep; 233(18):3371-81. PubMed ID: 27481049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
    Reeves S; Bertrand J; McLachlan E; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Dunn JT; Marsden P; Kessler R; Uchida H; Taylor D; Howard R
    J Clin Psychiatry; 2017 Jul; 78(7):e844-e851. PubMed ID: 28858444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
    Reeves S; Eggleston K; Cort E; McLachlan E; Brownings S; Nair A; Greaves S; Smith A; Dunn J; Marsden P; Kessler R; Taylor D; Bertrand J; Howard R
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):396-404. PubMed ID: 28643852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography.
    Clark-Papasavas C; Dunn JT; Greaves S; Mogg A; Gomes R; Brownings S; Liu K; Nwosu B; Marsden P; Joemon J; Cleij M; Kessler R; Howard R; Reeves S
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1001-9. PubMed ID: 24578318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers.
    Hamon-Vilcot B; Chaufour S; Deschamps C; Canal M; Zieleniuk I; Ahtoy P; Chretien P; Rosenzweig P; Nasr A; Piette F
    Eur J Clin Pharmacol; 1998 Jul; 54(5):405-9. PubMed ID: 9754984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient hyperproinsulinemia during treatment with clozapine and amisulpride.
    Rettenbacher MA; Hummer M; Fleischhacker WW; Lechleitner M
    J Clin Psychiatry; 2004 Jun; 65(6):878-9. PubMed ID: 15291669
    [No Abstract]   [Full Text] [Related]  

  • 8. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study.
    Liang Y; Cao C; Zhu C; Wang C; Zhang C; Dong F; Yang F; Deng H; Yu J; Tang J; Su L; Xin L; Hong L; Gao M; Tang M; Xie S; Lu S; Liu T; Xu X; Wang X; Li X; Wang X; Li Y; Zhang Y; Chen Z; Yu X
    Asia Pac Psychiatry; 2016 Sep; 8(3):241-4. PubMed ID: 27020720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
    Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
    J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
    Riedel M; Eich FX; Möller HJ
    Eur Psychiatry; 2009 Apr; 24(3):149-53. PubMed ID: 19070995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride for older patients with long-standing schizophrenia.
    Pridan S; Baruch Y; Swartz M; Barak Y
    J Clin Psychopharmacol; 2014 Dec; 34(6):736-7. PubMed ID: 25275673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prandial effect on the systemic exposure of amisulpride.
    Jang YJ; Jeong TC; Noh K; Baek IW; Kwon KI; Kim E; Yoon YR; Kang W
    Arch Pharm Res; 2014 Oct; 37(10):1325-8. PubMed ID: 24469600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.
    Glatard A; Guidi M; Delacrétaz A; Dubath C; Grosu C; Laaboub N; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2020 Mar; 59(3):371-382. PubMed ID: 31552612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.
    Bowskill SV; Patel MX; Handley SA; Flanagan RJ
    Hum Psychopharmacol; 2012 Sep; 27(5):507-13. PubMed ID: 22996618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.
    Rosenzweig P; Canal M; Patat A; Bergougnan L; Zieleniuk I; Bianchetti G
    Hum Psychopharmacol; 2002 Jan; 17(1):1-13. PubMed ID: 12404702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical issues with amisulpride in the management of patients with schizophrenia.
    Pani L; Villagrán JM; Kontaxakis VP; Alptekin K
    Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.